Viadur


Also found in: Dictionary, Wikipedia.

Viadur®

Duros® (leuprolide acetate) implant Oncology A device designed to provide once-yearly dosing of leuprolide for palliating advanced prostate CA. See Prostate cancer.
References in periodicals archive ?
Viadur is indicated to manage the symptoms associated with advanced prostate cancer, including pain, urinary problems and other symptoms typical of the disease.
Bayer is committed to continuing patient and physician support services for current and new Viadur patients.
In addition, Bayer HealthCare Pharmaceuticals has arranged for patients currently enrolled in the Viadur Continuous Care patient support program to receive an invitation to join the Us TOO International Patient Education and Support Network.
Viadur (leuprolide acetate) is the first and only titanium implant drug- delivery system using Duros technology to manage the symptoms associated with advanced (stage 4) prostate cancer, including pain, urinary problems and other symptoms typical of the disease.
Viadur is indicated in the palliative treatment of advanced prostate cancer.
Bayer's Viadur, for the treatment of prostate cancer will also be aligned with the Oncology unit.
Bayer also is marketing Viadur (TM)(b), the first and only, once-yearly, continuous testosterone suppression therapy to treat symptoms of advanced prostate cancer.
Along with Viadur and the cPSA test, a new addition to the Bayer men's health portfolio is Levitra(R) (vardenafil HCl), the first treatment choice in five years for erectile dysfunction.
Viadur delivers the drug leuprolide, a LH-RH agonist, which reduces the level of the hormone testosterone in the body.
Viadur is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components in Viadur.
Bayer also is marketing Viadur (TM)**, the first and only, once-yearly, continuous testosterone suppression therapy to treat symptoms of advanced prostate cancer.